Trial Profile

STEPP: A Phase 2, Open-Label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-Line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panitumumab (Primary) ; Doxycycline; Fluorouracil; Folinic acid; Hydrocortisone; Irinotecan; Sunscreens
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Registrational
Acronyms STEPP
Sponsors Amgen

Most Recent Events

06 Jun 2017 Results from STEPP and J-STEPP studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
05 Jun 2009 New trial record.
29 May 2009 Final quality-of-life results for prophylactic versus reactive skin toxicity treatment presented at ASCO 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com